Wedbush Reduces Earnings Estimates for Cogent Biosciences

Key Points

• Wedbush has decreased its Q3 2025 earnings per share estimate for Cogent Biosciences from ($0.31) to ($0.42), maintaining a "Neutral" rating with a $10.00 target price.
• The company reported an EPS of ($0.53), surpassing the consensus estimate of ($0.55) by $0.02.
• Recent insider activity includes the purchase of 2,777,777 shares by Director Fairmount Funds Management, increasing their ownership by 44.62%.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 earnings per share estimates for shares of Cogent Biosciences in a research note issued on Tuesday, August 5th. Wedbush analyst D. Nierengarten now forecasts that the technology company will post earnings of ($0.42) per share for the quarter, down from their previous forecast of ($0.31). Wedbush has a "Neutral" rating and a $10.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.47) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.46) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The technology company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.02.

COGT has been the subject of several other research reports. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a research note on Tuesday, June 17th. JPMorgan Chase & Co. upped their price target on Cogent Biosciences from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday. Jefferies Financial Group upped their price target on Cogent Biosciences from $23.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Citigroup upped their target price on Cogent Biosciences from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, July 18th. Finally, Leerink Partners upped their target price on Cogent Biosciences from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $18.70.

Cogent Biosciences Stock Performance

Shares of NASDAQ COGT traded down $0.20 during trading hours on Thursday, hitting $10.77. The stock had a trading volume of 335,800 shares, compared to its average volume of 2,006,559. The company has a market capitalization of $1.23 billion, a P/E ratio of -6.06 and a beta of 0.36. The firm's 50-day moving average price is $9.24 and its two-hundred day moving average price is $7.35. Cogent Biosciences has a 52 week low of $3.72 and a 52 week high of $12.97.

Hedge Funds Weigh In On Cogent Biosciences

Hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in shares of Cogent Biosciences by 84.3% during the fourth quarter. Janus Henderson Group PLC now owns 29,073 shares of the technology company's stock worth $227,000 after purchasing an additional 13,300 shares during the period. Ameriprise Financial Inc. lifted its holdings in Cogent Biosciences by 78.6% during the 4th quarter. Ameriprise Financial Inc. now owns 21,499 shares of the technology company's stock worth $168,000 after purchasing an additional 9,459 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Cogent Biosciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,604 shares of the technology company's stock worth $1,058,000 after purchasing an additional 17,741 shares during the last quarter. ProShare Advisors LLC raised its holdings in Cogent Biosciences by 30.5% in the 4th quarter. ProShare Advisors LLC now owns 31,074 shares of the technology company's stock valued at $242,000 after acquiring an additional 7,267 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Cogent Biosciences by 7.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 58,582 shares of the technology company's stock valued at $456,000 after acquiring an additional 3,831 shares in the last quarter.

Insider Activity at Cogent Biosciences

In other news, Director Fairmount Funds Management Llc purchased 2,777,777 shares of the firm's stock in a transaction that occurred on Thursday, July 10th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $24,999,993.00. Following the completion of the acquisition, the director directly owned 9,003,418 shares in the company, valued at approximately $81,030,762. The trade was a 44.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.29% of the company's stock.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.